Sangamo BioSciences reported $97.56M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Alaunos Therapeutics USD 1.52M 367K Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 96.05B 409M Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Cipla INR 434.34B 9.38B Sep/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 138.36M 7.5M Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Grifols EUR 23.15B 142.7M Dec/2025
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Merck USD 132.77B 2.97B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 204.54B 3.41B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 130.29B 1.23B Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Tectonic Therapeutic USD 237.03M 9.54M Jun/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026